Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


DH withdraws shortage protocol for fluoxetine 10mg

The government will withdraw its serious shortage protocol (SSP) for fluoxetine 10mg capsules on Friday evening.

Sufficient stocks of the 10mg strength are “now available to meet normal demand”, and from 11:55pm on Friday (October 25) they “must be prescribed and dispensed in the usual way, as the SSP will no longer be valid for use”, the Department of Health and Social Care (DH) said.

The protocols for fluoxetine 30mg and 40mg capsules will remain in effect, it added.

What are the serious shortage protocols?

The SSPs for fluoxetine – the first, and so far only, SSPs to be announced – were issued by the DH on October 3, granting pharmacists the ability to supply an alternative strength or form of fluoxetine 10mg, 30mg or 40mg capsules, without contacting a patient’s GP first.

More information and supporting guidance on SSPs can be found on the NHS Business Services Authority’s website.

How have the fluoxetine shortages affected you?

Related Content


Pharmacy Assistant
Paignton, Devon
£ Competitive

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts